NCT01490476View on ClinicalTrials.gov

Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

April 30, 2016

Study Completion Date

January 31, 2017

Conditions
Neurofibromatosis 2
Interventions
DRUG

RAD001

10 mg per os / day or 05mg per os / day with 12 month

Trial Locations (1)

92110

Hôpital Beaujon, 100 boulevard du Général Leclerc, Clichy

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01490476 - Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients | Biotech Hunter | Biotech Hunter